Medtronic Raises 2027 Forecasts Amid Heart Device Surge

Medtronic has revised its fiscal 2027 financial outlook upward, citing strong demand for its heart devices used in complex cardiovascular procedures. The medical technology giant now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from its previous forecast of 6.75% to 7.25%. Additionally, the company raised the lower end of its adjusted per-share profit forecast to $5.94, up from $5.90, while maintaining the upper end at $6.

Strategic Investments and Expanding Technology

The company also announced significant investments aimed at enhancing its growth in the cardiovascular market. Medtronic will invest $80 million in Pi-Cardia, a heart-valve repair device maker, with an option to fully acquire the company for $210 million. In another strategic move, Medtronic has invested $700 million in Cornerstone Robotics, which grants it distribution rights for a robotic surgical device in selected markets outside the United States.

CEO Geoff Martha expressed confidence in the company’s diversified performance across its business segments and its new growth platforms. During a recent earnings call, he highlighted the increasing demand for Medtronic's technologies, which are becoming integral in modern medical procedures.

Market Performance and Future Prospects

Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by an 88% surge in its pulsed field ablation portfolio, which is utilized in treating irregular heart rhythms. Overall, the company posted an adjusted quarterly per-share profit of $1.45 on revenues of $9.76 billion, surpassing analysts’ expectations of $1.39 per share on $9.55 billion in sales, according to LSEG data.

The company’s financial chief, Thierry Pieton, also noted that Medtronic received tariff refunds that nearly offset the duties paid during the quarter. However, future refunds have not been factored into the company’s outlook. Martha emphasized the importance of penetrating emerging markets with robotic surgery technologies, noting that the adoption rate for soft tissue robotic surgery in these regions is currently below 1%.

Medtronic continues to prioritize high-growth segments within the medtech industry, focusing on large patient pools and significant market opportunities. Martha remarked on the company’s strategic mergers and acquisitions, indicating a steady pace of activity aimed at capturing these expanding market segments.